Read + Share
Xu B. Dalpiciclib in advanced breast cancer: introducing CDK4/6 inhibitors as a
first-line treatment might not be the best strategy - Author's reply. Lancet Oncol 2023;24:e357.
PMID: 37657472
|
 |
|
Xu B. Dalpiciclib in advanced breast cancer: introducing CDK4/6 inhibitors as a
first-line treatment might not be the best strategy - Author's reply. Lancet Oncol 2023;24:e357.
PMID: 37657472
|
|
|
|